| Background | Eculizumab is a recombinant humanized monoclonal antibody directed against the complement protein C5. The complement system pathways are the first line of defense against infectious threats. Their activation plays a critical role in innate and adaptive immune responses. Unfortunately, deregulations within the system have been shown to drive severe immune and inflammatory disorders. Eculizumab biosimilar contains human constant regions from human IgG2 sequences and human IgG4 sequences and murine complementarity-determining regions grafted onto the human framework light-and heavy-chain variable regions. Eculiz umab biosimilaris composed of two 448 amino acid heavy chains and two 214 amino acid light chains and has a molecular weight of approximately 148 kDa. |
Information sourced from Uniprot.org
